AKTX — Q2 2026 Financial Report Analysis

Overview

Akari Therapeutics, a UK-incorporated biotech listed in the US through American Depositary Shares (ADSs), has no product revenue, so its quarterly report comes down to three questions: how much it spent, on what, and how long its cash lasts. For the quarter ended June 30, 2026, the answer is that spending shifted clearly toward its one lead drug candidate. Research and development (R&D) spending rose to $2.1 million from $0.7 million a year earlier, and almost all of that money went to outside labs and manufacturers preparing AKTX-101 for its first human trials. Net loss for the quarter was $4.8 million, up from $1.9 million. Cash at quarter-end was $7.7 million. Management says that covers operations only "into December 2026", and the filing again flags "substantial doubt" about the company's ability to continue as a going concern (an auditor-style warning that the company does not currently have enough money to run for the next 12 months).

The company Akari is now is also different from the one many older investors remember. It no longer develops complement inhibitors: the nomacopan programs (HSCT-TMA, PAS-nomacopan) and PHP-303 were suspended in December 2024 while it looks for a partner to take them on. Akari now describes itself as an oncology company developing ADCs (antibody-drug conjugates: an antibody that homes in on a protein on cancer cells, attached to a toxic "payload" that kills the cell). Its distinguishing bet is the payload. PH1 is a spliceosome modulator, meaning it disrupts how cancer cells process their RNA. Most marketed ADCs instead use payloads that attack the cell's internal scaffolding or damage its DNA.

At a glance

• R&D up 211% to $2.1M. Spending on outside ADC preclinical work went from $0.15M to $1.87M, which is what a lab program looks like once manufacturing for a human trial begins.
• $7.7M cash vs. $12.9M of unpaid bills and accruals. Accounts payable and accrued expenses are now larger than the cash balance, and the company states its cash lasts only into December 2026.
• Share count up 55% in six months. Ordinary shares outstanding rose from 90.5 billion to 140.0 billion between December 31 and June 30, because each funding round is paid for by issuing new shares.

The numbers

All figures are in US$ millions unless stated, for the three months ended June 30.

Loss per share rounds to zero because Akari has about 140 billion ordinary shares in issue (each ADS represents 80,000 of them since a March 31, 2026 ratio change), so the per-share figure says nothing useful. The six-month picture is distorted by write-downs: the first-half net loss was $19.3 million, against $5.6 million a year earlier, but $12.1 million of that is the non-cash impairment covered below.

Where the money went

The rise in R&D comes from one line. "ADC preclinical development", which covers payments to outside vendors such as contract manufacturers and labs, was $1.87 million in the quarter, up from $0.15 million. For the first half it was $3.11 million, up from $0.16 million. In December 2025 Akari picked WuXi Biologics/XDC to produce GMP material for AKTX-101. GMP is the manufacturing standard required for drug given to people. WuXi is also handling related IND-enabling work: the safety and manufacturing package a company must file with the FDA (the Investigational New Drug application) before a human trial can start.

Other costs moved the opposite way. R&D personnel costs fell to $0.16 million from $0.52 million, which the filing puts down to lower stock-based compensation and lower cash salaries. General and administrative (G&A) costs, meaning overhead such as executives, lawyers and listing costs, were roughly flat in the quarter at $2.53 million. For the half they fell 9.1% to $4.69 million, mainly because of $0.4 million less stock-based compensation. Overhead still exceeds R&D, though. In Q2, G&A was $2.53 million against $2.08 million of R&D, so more than half of operating spending went on running a public company rather than on the drug itself.

Pipeline: what the spending is buying

• AKTX-101 (preclinical): an ADC that targets Trop-2, a protein found on many solid tumours including lung, breast and bladder, and carries the PH1 payload. Management's target, unchanged since December 2025, is to start clinical trials by the middle of 2027. In April 2026 it presented lab data at AACR showing AKTX-101 killed cancer cell lines at lower concentrations than Trop-2 ADCs with conventional topoisomerase I-inhibitor payloads, including sub-nanomolar potency in every bladder cancer line tested. Bladder cancer is where the first human trial is planned. A separate ASCO 2026 abstract showed synergy with KRAS inhibitors in pancreatic cancer models. All of this is cell-line and animal data, and none of it has been tested in patients.
• AKTX-102: an earlier-stage ADC directed at CEACAM5.
• Whitehawk collaboration (July 2026): Akari will run preclinical studies combining its PH1 payload with Whitehawk Therapeutics' topoisomerase I-inhibitor ADC platform. The filing does not disclose any payment to Akari under this agreement.
• Patents: during the half Akari received an Australian patent covering the PH1 payload and a European composition-of-matter patent for its thailanstatin-based payloads.

Takeaway: Akari is now spending real money on getting AKTX-101 into the clinic, with outside preclinical costs up more than tenfold year on year. But the $7.7M in cash funds it only "into December 2026", against a first-patient target of mid-2027. That leaves at least one more funding round, and more likely several, between today and any human data. The financing terms and the dilution they bring matter more to shareholders than anything in this quarter's income statement.

What the headline numbers hide

• The cash burn looks lower than it is. First-half operating cash outflow was $5.6 million, but that already includes a $1.55 million increase in accounts payable, accrued expenses and other current liabilities. Put simply, the company held on to cash partly by paying suppliers later. Without that build-up, operating cash use would have been about $7.2 million for the half. Accounts payable ($9.4M) plus accrued expenses ($3.5M) total $12.9 million, against $7.7 million of cash. Current liabilities of $13.9 million exceed current assets of $8.3 million, which leaves negative working capital of about $5.6 million.
• The cash balance rose, but only because of new shares. Cash went up $2.5 million in the half because financing brought in $8.1 million: $5.2 million net from the May 2026 private placement (ADSs sold at $3.74 with three series of warrants attached), $3.0 million from warrant exercises, and $0.2 million from the second closing of the December 2025 round, minus insurance-financing and note repayments. Operations consumed $5.6 million.
• The six-month loss is mostly a write-down, not spending. In Q1, Akari wrote off all $8.43 million of goodwill and cut the value of the AKTX-101 IPR&D asset (in-process R&D: the value assigned to an unfinished drug program acquired in the 2024 Peak Bio merger) by $3.7 million, to $30.3 million. The filing says a "sustained decline in the Company's market capitalization" triggered the test. These charges cost no cash. They do mean the balance sheet now values AKTX-101 lower, partly to reflect "capital availability considerations". Net of an $0.86 million deferred tax benefit, the impairments explain about $11.3 million of the $13.7 million rise in first-half net loss.
• Last year's quarter was flattered by a one-off. Q2 2025 included a $1.19 million gain from settling old vendor bills for less than was owed. Without it, last year's Q2 net loss would have been about $3.1 million instead of $1.9 million, so the underlying increase in this year's loss is smaller than the 153.7% headline suggests. Operating loss, which excludes that gain, rose 47.5%.
• More than three-quarters of the balance sheet is a single intangible asset. Of $38.6 million in total assets, $30.3 million is the AKTX-101 IPR&D intangible. Shareholders' equity of $18.6 million rests almost entirely on that one valuation, which has already been cut once this year.
• Dilution keeps going after quarter-end. After June 30, Akari issued another 196,572 ADSs: prefunded-warrant exercises, an RSU settlement, 117,647 ADSs paid to placement agent Paulson for the May round, and 36,000 commitment ADSs to White Lion. The White Lion equity line, which lets Akari sell up to $25 million of new shares to White Lion over time at prices tied to the market, became usable once its registration was declared effective on July 7, 2026. That gives the company a funding source, but every draw on it means more new shares.

Outlook

Management gives no financial guidance. Its stated plan is to keep GMP manufacturing and the IND-enabling data package on track for AKTX-101 to enter the clinic by mid-2027, and to keep expanding the PH1 pipeline only "as capital and priorities permit". The 10-Q says the company has "additional funding activities in progress" but "no commitments for future external funding".

Our read: R&D spending will rise further as GMP batches and toxicology studies run toward an IND filing. Even the current pace of roughly $3.6–4.6 million a quarter in operating expenses (excluding write-downs) equals roughly half to 60% of the June cash balance. The White Lion line and the outstanding $3.74 Series H/I/J warrants are the most likely next sources of money. The warrants only bring in cash if the ADS price stays above their exercise price. The things to watch in the Q3 10-Q, due around mid-November 2026, are: (1) whether the runway statement moves beyond December 2026; (2) how much was drawn from White Lion and at what price; (3) whether the payables balance starts to come down; and (4) any change to the mid-2027 clinical-start target. Any delay in a program at this stage usually traces back to funding before anything else.

Source: Akari Therapeutics Form 10-Q for the quarter ended June 30, 2026, filed August 13, 2026.